Summary
2008, Vol. 24, No. 2, Pages 369-376

Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study

Anne Dornhorsta, Hans-Joachim Lüddekeb, Marek Honkac, Ralf W. Ackermannd, Markus Meriläinend, Baptist Gallwitze and Seamus Sreenanf
Address for correspondence:Professor Seamus Sreenan, Dept of Endocrinology, Connolly Hospital, Blanchardstown, Dublin 15, Ireland. Tel.: +353 1 646 5748, Fax: +353 1 646 5310,



ABSTRACT

Objective: PREDICTIVE is a multi-national, prospective, observational study, assessing the safety and efficacy of insulin detemir in patients with diabetes.

Research design and methods: The European cohort includes 20531 patients with diabetes (7420 type 1) from 11 countries. A subgroup of 4782 type 1 patients were transferred from a basal-bolus regimen with NPH insulin (n = 3117) or insulin glargine (n = 1665) to insulin detemir basal-bolus therapy; or from a human insulin basal-bolus regimen (n = 570) to insulin detemir/insulin aspart (part of the pre-study NPH group). Mean follow-up was 14.4 weeks. The primary endpoint was serious adverse drug reactions (SADRs), including major hypoglycaemia. Secondary endpoints were: incidence of overall and nocturnal hypoglycaemia; haemoglobin A1c (HbA1c); fasting glucose; within-patient fasting glucose variability; and change in body weight.

Results: SADRs were reported by 62 (2.0%) patients previously receiving NPH insulin, 45 (2.7%) patients previously receiving insulin glargine and seven (1.2%) patients previously receiving human basal-bolus insulins. Major hypoglycaemia was significantly reduced in NPH insulin (55%), insulin glargine (51%), and human basal-bolus insulin groups (54%; p < 0.0001 for all). Total and nocturnal hypoglycaemic episodes were also significantly reduced in all groups (p < 0.0001 for all). HbA1c was reduced in patients previously receiving NPH insulin (0.5%), insulin glargine (0.4%), and human basal-bolus insulins (0.6%; p < 0.0001 for all). Mean fasting glucose and within-patient fasting glucose variability significantly decreased in all patients (p < 0.0001 for all). Body weight remained stable.

Conclusions: In this open-label, prospective, observational study, insulin detemir basal-bolus therapy improved glycaemic control and reduced hypoglycaemia with weight neutrality in type 1 patients in actual clinical practice.

PDF (311 KB) | PDF Plus (312 KB)

Forward Links to Citing Articles

Selim Kurtoglu, Mehmet Emre Atabek, Ceyhun Dizdarer, Ozgur Pirgon, Pinar Isguven, Sevil Emek. (2009) Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE™ observational study. Pediatric Diabetes
Online publication date: 1-Mar-2009.
CrossRef
Allen B King. (2009) Insulin detemir: a better basal insulin for the management of diabetes?. Expert Review of Endocrinology & Metabolism 4:1, 15-23
Online publication date: 1-Feb-2009.
CrossRef
S. Sreenan, A. Virkamäki, K. Zhang, J. B. Hansen. (2009) Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE™ study. International Journal of Clinical Practice 62:12, 1971-1980
Online publication date: 1-Jan-2009.
CrossRef
(2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:9, i-xvi
Online publication date: 1-Oct-2008.
CrossRef


Users who read this article also read:

Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study
L. F. Meneghini, A. Dornhorst, S. Sreenan
Current Medical Research and Opinion, Apr 2009, Vol. 25, No. 4, Pages 1029-1035.
Summary | Full Text | PDF (266 KB) | PDF Plus (292 KB) | Add to Favorites | Related 
 

Prev. Article | Next Article
View/Print PDF (311 KB)
View PDF Plus (312 KB)
Add to favourite
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Authors:
Anne Dornhorst
Hans-Joachim Lüddeke
Marek Honka
Ralf W. Ackermann
Markus Meriläinen
Baptist Gallwitz
Seamus Sreenan
Keywords:
Glycaemic control
Hypoglycaemia
Insulin detemir
Observational
Type 1 diabetes
Weight neutrality